Literature DB >> 22860183

ACS chemical neuroscience molecule spotlight on BMS-708163.

Corey R Hopkins1.   

Abstract

BMS-708163 is a novel, sulfonamide containing γ-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).

Entities:  

Keywords:  Alzheimer's disease; GSI; amyloid hypothesis; gamma-secretase inhibitors

Mesh：

Substances：

Year:  2012        PMID： 22860183      PMCID： PMC3369796          DOI： 10.1021/cn3000179

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  9 in total

Review 1.  ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic.

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

2.  ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2010-08-18       Impact factor: 4.418

Review 3.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

Review 4.  The molecular pathology of Alzheimer's disease.

Authors:  D J Selkoe
Journal:  Neuron       Date:  1991-04       Impact factor: 17.173

5.  Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.

Authors:  Kevin W Gillman; John E Starrett; Michael F Parker; Kai Xie; Joanne J Bronson; Lawrence R Marcin; Kate E McElhone; Carl P Bergstrom; Robert A Mate; Richard Williams; Jere E Meredith; Catherine R Burton; Donna M Barten; Jeremy H Toyn; Susan B Roberts; Kimberley A Lentz; John G Houston; Robert Zaczek; Charles F Albright; Carl P Decicco; John E Macor; Richard E Olson
Journal:  ACS Med Chem Lett       Date:  2010-03-22       Impact factor: 4.345

6.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Authors:  R Vassar; B D Bennett; S Babu-Khan; S Kahn; E A Mendiaz; P Denis; D B Teplow; S Ross; P Amarante; R Loeloff; Y Luo; S Fisher; J Fuller; S Edenson; J Lile; M A Jarosinski; A L Biere; E Curran; T Burgess; J C Louis; F Collins; J Treanor; G Rogers; M Citron
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  ACS chemical neuroscience molecule spotlight on Begacestat (GSI-953).

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2012-01-18       Impact factor: 4.418

Review 9.  Alzheimer's disease: from pathology to therapeutic approaches.

Authors:  Roland Jakob-Roetne; Helmut Jacobsen
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.